pteridines has been researched along with Chronic Hepatitis C in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In healthy volunteers, low doses of GS-9620 (2, 4 and 6 mg) induced significant expression of peripheral interferon-stimulated-gene (ISG) mRNA in the absence of detectable serum interferon-α and systemic adverse events (AEs)." | 6.80 | Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C. ( Freilich, B; Gaggar, A; Gruener, D; Hassman, D; Hill, J; Jacobson, IM; Lawitz, E; Marbury, T; Massetto, B; McHutchison, JG; Mogalian, E; Nguyen, AH; Pflanz, S; Rodriguez-Torres, M; Subramanian, GM; Webster, L, 2015) |
| " In healthy volunteers, low doses of GS-9620 (2, 4 and 6 mg) induced significant expression of peripheral interferon-stimulated-gene (ISG) mRNA in the absence of detectable serum interferon-α and systemic adverse events (AEs)." | 2.80 | Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C. ( Freilich, B; Gaggar, A; Gruener, D; Hassman, D; Hill, J; Jacobson, IM; Lawitz, E; Marbury, T; Massetto, B; McHutchison, JG; Mogalian, E; Nguyen, AH; Pflanz, S; Rodriguez-Torres, M; Subramanian, GM; Webster, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Younossi, ZM | 1 |
| Stepanova, M | 1 |
| Younossi, I | 1 |
| Papatheodoridis, G | 1 |
| Janssen, HLA | 1 |
| Agarwal, K | 1 |
| Nguyen, MH | 1 |
| Gane, E | 1 |
| Tsai, N | 1 |
| Nader, F | 1 |
| Lawitz, E | 1 |
| Gruener, D | 1 |
| Marbury, T | 1 |
| Hill, J | 1 |
| Webster, L | 1 |
| Hassman, D | 1 |
| Nguyen, AH | 1 |
| Pflanz, S | 1 |
| Mogalian, E | 1 |
| Gaggar, A | 1 |
| Massetto, B | 1 |
| Subramanian, GM | 1 |
| McHutchison, JG | 1 |
| Jacobson, IM | 1 |
| Freilich, B | 1 |
| Rodriguez-Torres, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus In[NCT01591668] | Phase 1 | 51 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pteridines and Chronic Hepatitis C
| Article | Year |
|---|---|
Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chron | 2019 |
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Cytokines; Female; Gene Expression; Genotype; | 2015 |